Paul Tlucek, MD
Retina Specialist · Portland, ORNPI 1982800470
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,460 of the $2,244 with a category attached, or 65.0%. 5 manufacturers reported payments, led by Novartis at 45.9% of the total.
Across 15 payments — averaging $149.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Genentech USA, Inc.$633
- Regeneron$464
- Regeneron Healthcare Solutions, Inc.$98
- Carl Zeiss Meditec AG$19
Across 96 payments — averaging $50,091 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.6M
- Genentech, Inc.$1.2M
- Hoffmann-la Roche Limited$16K
- Aerie Pharmaceuticals, Inc.$4K
What the payments were for
- Travel & lodging$76534%
- Food & beverage$1,46065%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $1,030 |
| Genentech USA, Inc. | 5 | $633 |
| Regeneron | 4 | $464 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$539
- EYLEA HD$386
- EYLEA$268
- BUPARLISIB$122
How this compares
$2,244 in reported general payments places this provider in the 55th percentile of 36 retina specialist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 147 | $5,201 |
| Ketorolac Tromethamine | 52 | $2,465 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 47 | $612 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $193 |
| Ofloxacin | 18 | $186 |
| Latanoprost | 23 | $151 |
| Brimonidine Tartrate | 26 | $143 |
| Timolol Maleate | 17 | $121 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Portland
- Brian Chan KaiPortland$155K
- Brandon LujanPortland$33K
- Andreas LauerPortland$17K
- Sirichai PasadhikaPortland$6K
- David WilsonPortland$5K
- Harpal SandhuPortland$3K
- Aristomenis ThanosPortland$3K
- Michael LeePortland$3K
- Kavita BhavsarPortland$2K
- Apurva PatelPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.